Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI). Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Benefit of inhaled corticosteroids (ICS) in asthmatic patients with bronchial hyperresponsiveness (BHR) to mannitol and low fractional exhaled nitric oxide (FeNO) levels Source: International Congress 2017 – Monitoring asthma control Year: 2017
Optimising inhaled corticosteroid (ICS) dose using exhaled nitric oxide (eNO) measurements Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study Source: Eur Respir J 2006 Oct 01;28(4):748-755 Year: 2006
Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children Source: Eur Respir J 2002; 20: 630-634 Year: 2002
Effect of inhaled steroids and long-acting β2 agonists on exhaled nitric oxide (eNO) in asthmatic children Source: Eur Respir J 2004; 24: Suppl. 48, 270s Year: 2004
Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Influence of fluticasone propionate on levels of exhaled nitric oxide in asthmatic children: a dose response study Source: Eur Respir J 2001; 18: Suppl. 33, 40s Year: 2001
Effect of systemic and extra-fine particle inhaled corticosteroids on corrected alveolar nitric oxide (CANO) in COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
The clinical utility of exhaled nitric oxide (eNO) in asthma, the first 1,000 patients Source: Eur Respir J 2004; 24: Suppl. 48, 304s Year: 2004
Stability of exhaled nitric oxide (FE NO) in patients with severe, steroid-dependent asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008
Prospective nitrite, nitrate and cys-leukotriene (cys-LTs ) measurements in EBC (exhaled breath condensate) in asthmatic children and relation to outcome during inhaled steroid (IS) reduction Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Comparison of the anti-inflammatory effects of extra-fine HFA-beclomethasone (BDP) versus fluticasone (FP)-DPI on inflammatory markers in exhaled breath in childhood asthma Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007
Exhaled nitric oxide (FENO) in the assessment of the safety of allergen immunotherapy (SIT) in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 209s Year: 2006
Effect of adding montelukast to budesonide treatment on exhaled nitric oxide in mild to moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 259s Year: 2004
Cough sensitivity, airway responsiveness and exhaled nitric oxide (eNO) for predicting the response to bronchodilator therapy (BDT) in patients with chronic non-productive cough Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control Year: 2010
Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma Source: Eur Respir J 2004; 24: 932-937 Year: 2004
Natural allergen exposure and nitric oxide (NO) metabolites in exhaled air condensate (EAC) of children with mite bronchial asthma (BA) Source: Eur Respir J 2003; 22: Suppl. 45, 131s Year: 2003
Dynamics of the nitric oxide metabolites in the exhaled breath condensate (EBC) in atopic asthma (BA) children receiving various treatment options Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013